A Rising NT-proBNP in a Patient Who Feels Fine: What GUIDE-IT Actually Settled
Stable ambulatory HFrEF, no clinical signs of decompensation, but a biomarker that has climbed across three consecutive visits. The largest trial built to answer whether that trend should trigger treatment found, unambiguously, that it shouldn't drive the decision alone.
G.P., a 67-year-old man, taught and coached competitive debate for thirty years before retiring, and still spends most weekends judging tournaments around the region — long days on his feet in hotel ballrooms, work he genuinely enjoys and has no plan to give up. He was diagnosed with nonischemic HFrEF, EF 30%, fourteen months ago after one hospitalization for volume overload, and has been on optimized quadruple GDMT for over a year without another admission. Today he reports feeling generally well — some weeks more tired than others, nothing he can pin to a pattern, no orthopnea, no paroxysmal nocturnal dyspnea, no weight gain on his home log. His exam is unremarkable: no jugular venous distension, no peripheral edema, clear lungs. But his NT-proBNP, checked at each of his last three visits, has climbed steadily — 850, then 1150, then 1450 pg/mL today — a real upward trend across nine months despite a clinical picture that hasn't changed.
Natriuretic-peptide-guided therapy was built on real physiologic logic: GDMT uptitration tends to lower BNP and NT-proBNP, and patients whose levels fail to fall despite treatment have worse outcomes. An earlier meta-analysis of eleven randomized trials found biomarker-guided management associated with a 38% relative reduction in mortality compared with usual clinical care — a genuinely promising signal that made GUIDE-IT, the large, dedicated trial built to confirm it, feel like a formality rather than a real test. It wasn't. GUIDE-IT randomized patients with high-risk HFrEF to NT-proBNP-guided titration, target level under 1,000 pg/mL, against usual guideline-based care, and was stopped early for futility once 894 of a planned 1,100 patients had enrolled — the primary endpoint occurred in 37% of both groups, hazard ratio 0.98. It remains the single largest, most rigorous test of the exact question G.P.'s rising number now raises.
Heart failure clinic, routine follow-up
Three consecutive visits climbing is a real trend, not one noisy value. The meta-analysis behind biomarker-guided therapy showed a substantial mortality signal, and I'd rather escalate his GDMT now, target under 1,000, than wait for his exam to catch up to what the number may already be telling us.
I'm not dismissing GUIDE-IT — I'm saying a rising trend in one specific patient is a different situation than the trial's aggregate null result.
GUIDE-IT tested exactly this question, in a similarly high-risk HFrEF population, at real scale — and found no benefit, stopped early for futility with the primary endpoint identical between groups. Escalating his diuretic or other GDMT based on a number alone, with no clinical sign of volume overload, has real, non-hypothetical costs: hypotension, renal injury, electrolyte disturbance. I wouldn't change his medications today.
I take the trend seriously as information — I just don't think GUIDE-IT leaves room to treat it as a dosing instruction on its own.
I don't think the choice is between acting on the number and ignoring it. We haven't actually reviewed his adherence, his sodium intake, or how consistently he's logging his weight in some time — a rising trend is a reasonable prompt to look harder at all of that and bring him back sooner, before deciding whether any medication needs to change at all.
Agreed: no medication change today; review adherence, dietary sodium, and home weight-log consistency in detail, and bring him back in four weeks instead of the usual three months, with a repeat NT-proBNP and full clinical exam at that visit.
Not agreed, and carried forward explicitly rather than smoothed over:
The Heart Failure Cardiologist's original preference for biomarker-guided escalation would be revisited directly, treating the continued rise as harder to dismiss as adherence or diet alone.
The Clinical Pharmacologist's and Primary Care Physician's position is reinforced — the number was real information, but the exam-guided approach found what actually needed addressing.
The Heart Failure Cardiologist maintained, even after agreeing to today's plan, that a persistent three-visit trend deserves real weight beyond what GUIDE-IT's aggregate result implies — accepted as a reason to shorten the follow-up interval, not as a retraction of that concern.